NFATC1 and prostate cancer: Exposure of RANKL-primed precursors to 10% prostate cancer CM resulted in significant increase in the percentage of precursors (69-97% for PC3, 80-93% for LNCaP) exhibiting nuclear NFATc1 compared to negative control (Figure 6E-G).